Effect of Neoadjuvant Chemotherapy on Angiogenesis and Cell Proliferation of Breast Cancer Evaluated by Dynamic Enhanced Magnetic Resonance Imaging

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2022 Aug 2

PMID 35915805

Authors

Lifang Chang

Honglin Lan

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is the uncontrolled proliferation of breast epithelial cells under the action of various carcinogenic factors. The evaluation of early efficacy of neoadjuvant chemotherapy for breast cancer is helpful to change the treatment plan in time. On this basis, dynamic contrast enhancement magnetic resonance imaging (DCE-MRI) was used to evaluate the effects of neoadjuvant chemotherapy on angiogenesis and cell proliferation in breast cancer.

Objective: To evaluate the effect of neoadjuvant chemotherapy on angiogenesis and cell proliferation of breast cancer by dynamic enhanced DCE-MRI.

Method: 80 breast cancer patients were divided into the routine chemotherapy group (3 cycles) and neoadjuvant chemotherapy groups (3 cycles) of 40 cases each from January 2018 to June 2021. Based on conventional imaging, DCE-MRI was performed with Intera Achieva 3.0 TMR superconducting MR scanner before and after treatment. The quantitative indexes, MRI parameters, cell proliferation expression, and DCE-MRI angiogenesis were compared between the two groups.

Result: The inhibition rate, Vepost, Ktranspre, ADC, Bax, Alexi, and Aurora in the neoadjuvant chemotherapy group were significantly higher than those in the conventional chemotherapy group ( < 0.05), while Kep, Ktrans, and Nek2 were significantly lower than those in the conventional chemotherapy group ( < 0.05). Vepre (cm), Ktranspre (ml/min/100 cm), and Ve had no significant difference ( > 0.05).

Conclusion: The quantitative parameters, MRI parameters, proliferation, and expression of DCE-MRI in breast cancer patients with different chemotherapy regimens are quite different. They can be applied to the diagnosis of neoadjuvant chemotherapy in breast cancer patients with angiogenesis and cell proliferation.

Citing Articles

DCE-MRI quantitative analysis and MRI-based radiomics for predicting the early efficacy of microwave ablation in lung cancers.

Yang C, Zhu F, Yang J, Wang M, Zhang S, Zhao Z Cancer Imaging. 2025; 25(1):26.

PMID: 40065426 PMC: 11892232. DOI: 10.1186/s40644-025-00851-7.

Retracted: Effect of Neoadjuvant Chemotherapy on Angiogenesis and Cell Proliferation of Breast Cancer Evaluated by Dynamic Enhanced Magnetic Resonance Imaging.

International B Biomed Res Int. 2023; 2023:9784125.

PMID: 37388341 PMC: 10307096. DOI: 10.1155/2023/9784125.

References

Thibault G, Tudorica A, Afzal A, Chui S, Naik A, Troxell M . DCE-MRI Texture Features for Early Prediction of Breast Cancer Therapy Response. Tomography. 2017; 3(1):23-32. PMC: 5500247. DOI: 10.18383/j.tom.2016.00241. View

Cheng X, Chen C, Xia H, Zhang L, Xu M . 3.0 T Magnetic Resonance Functional Imaging Quantitative Parameters for Differential Diagnosis of Benign and Malignant Lesions of the Breast. Cancer Biother Radiopharm. 2020; 36(6):448-455. DOI: 10.1089/cbr.2019.3040. View

Jordan B, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L . Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia. 2005; 7(5):475-85. PMC: 1501160. DOI: 10.1593/neo.04628. View

. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2017; 19(1):27-39. PMC: 5757427. DOI: 10.1016/S1470-2045(17)30777-5. View

Radisky E, Radisky D . Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord. 2007; 8(3):279-87. DOI: 10.1007/s11154-007-9037-1. View

Yang Z, Chen X, Zhang T, Cheng F, Liao Y, Chen X . Quantitative Multiparametric MRI as an Imaging Biomarker for the Prediction of Breast Cancer Receptor Status and Molecular Subtypes. Front Oncol. 2021; 11:628824. PMC: 8481692. DOI: 10.3389/fonc.2021.628824. View

Andreassen M, Goa P, Sjobakk T, Hedayati R, Eikesdal H, Deng C . Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI. MAGMA. 2019; 33(2):317-328. PMC: 7109176. DOI: 10.1007/s10334-019-00778-8. View

Kang S, Kim H, Kim H . Evaluating the Relationship Between Dynamic Contrast-Enhanced MRI (DCE-MRI) Parameters and Pathological Characteristics in Breast Cancer. J Magn Reson Imaging. 2020; 52(5):1360-1373. DOI: 10.1002/jmri.27241. View

Wang C, Wei W, Santiago L, Whitman G, Dogan B . Can imaging kinetic parameters of dynamic contrast-enhanced magnetic resonance imaging be valuable in predicting clinicopathological prognostic factors of invasive breast cancer?. Acta Radiol. 2017; 59(7):813-821. DOI: 10.1177/0284185117740746. View

10.

diFlorio-Alexander R, Slanetz P, Moy L, Baron P, Didwania A, Heller S . ACR Appropriateness Criteria Breast Imaging of Pregnant and Lactating Women. J Am Coll Radiol. 2018; 15(11S):S263-S275. DOI: 10.1016/j.jacr.2018.09.013. View

11.

Pinker K, Helbich T, Morris E . The potential of multiparametric MRI of the breast. Br J Radiol. 2016; 90(1069):20160715. PMC: 5605035. DOI: 10.1259/bjr.20160715. View

12.

Leithner D, Moy L, Morris E, Marino M, Helbich T, Pinker K . Abbreviated MRI of the Breast: Does It Provide Value?. J Magn Reson Imaging. 2018; 49(7):e85-e100. PMC: 6408315. DOI: 10.1002/jmri.26291. View

13.

Lee J, Kim S, Kang B . Prognostic Factors of Disease Recurrence in Breast Cancer Using Quantitative and Qualitative Magnetic Resonance Imaging (MRI) Parameters. Sci Rep. 2020; 10(1):7598. PMC: 7200757. DOI: 10.1038/s41598-020-64564-6. View

14.

Dong H, Kang L, Cheng S, Zhang R . Diagnostic performance of dynamic contrast-enhanced magnetic resonance imaging for breast cancer detection: An update meta-analysis. Thorac Cancer. 2021; 12(23):3201-3207. PMC: 8636198. DOI: 10.1111/1759-7714.14187. View

15.

Zhao Y, Schaafsma E, Cheng C . Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy. Cancer Med. 2020; 9(17):6281-6295. PMC: 7476842. DOI: 10.1002/cam4.3284. View

16.

Liu L, Mei N, Yin B, Peng W . Correlation of DCE-MRI Perfusion Parameters and Molecular Biology of Breast Infiltrating Ductal Carcinoma. Front Oncol. 2021; 11:561735. PMC: 8548684. DOI: 10.3389/fonc.2021.561735. View

17.

Xu T, Zhang L, Xu H, Kang S, Xu Y, Luo X . Prediction of low-risk breast cancer using quantitative DCE-MRI and its pathological basis. Oncotarget. 2018; 8(69):114360-114370. PMC: 5768409. DOI: 10.18632/oncotarget.22267. View

18.

Tafreshi N, Kumar V, Morse D, Gatenby R . Molecular and functional imaging of breast cancer. Cancer Control. 2010; 17(3):143-55. DOI: 10.1177/107327481001700302. View

19.

Li H, Zuo T, Zeng H, Zheng R, Yang L, Li H . [Clinical features and prognostic analysis of female breast cancer in different diagnosed ages]. Zhonghua Zhong Liu Za Zhi. 2021; 43(1):126-131. DOI: 10.3760/cma.j.cn112152-20191212-00801. View

20.

Lee S, Ko K, Jung H, Koh J, Park A . The additional utility of ultrafast MRI on conventional DCE-MRI in evaluating preoperative MRI of breast cancer patients. Eur J Radiol. 2020; 124:108841. DOI: 10.1016/j.ejrad.2020.108841. View